Jim Cramer: Buy Target, Yum! Brands, and These 2 Stocks

Jim Cramer made the following calls on October 18th, 2013. What do you think about his picks?

Target Corp. (NYSE:TGT): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on September 10, 2012. The stock’s 52-week high is $73.50, and its 52-week low is $58.01. Cramer was optimistic about Target, saying that he thinks that retail has been oversold recently. This creates an opportunity to buy, as the stock has room to move upward to its levels at the start of the summer, if not higher.

tgt-20131021

Yum! Brands, Inc. (NYSE:YUM): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Sell on July 13, 2012. The stock’s 52-week high is $75.13, and its 52-week low is $59.68. Cramer had good things to say about food conglomerate Yum! Brands, which owns such names as Kentucky Fried Chicken. The company’s stock took a hit earlier this month when it released weak earnings in the third quarter, which were tied in to controversy over its food products in China.

yum-20131021

Ruth’s Hospitality Group Inc. (NASDAQ:RUTH): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on June 7, 2013. The stock’s 52-week high is $13.76, and its 52-week low is $6.05. Cramer was a fan of Ruth’s Hospitality Group, the name behind Ruth’s Chris Steakhouse. Though the stock has been rather stagnant of late, the name may be able to pick up momentum if the economy continues to rebound.

ruth-20131021

St. Jude Medical Inc. (NYSE:STJ): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on April 27, 2011. The stock’s 52-week high is $57.17, and its 52-week low is $30.25. Cramer sat down with Daniel Starks, the chairman, president, and CEO of St. Jude, to discuss the company’s directions for future growth. Starks said that St. Jude was leading the way in the transition from yesterday’s medical devices to the latest, cutting edge models, including the Nanostim miniature pacemaker, which, though it will likely not get FDA approval until sometime after 2014, could revolutionize the discipline.

stj-20131021

Don’t Miss: Here’s Why Apple’s E-Commerce Chief Is Going to EBay.